Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BLUSFNASDAQ:EPZMNASDAQ:INSMNASDAQ:TBPHNASDAQ:TPTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsINSMInsmed$25.79+2.1%$27.27$18.08▼$32.00$3.83B0.921.75 million shs242,724 shsTBPHTheravance Biopharma$9.18-0.4%$9.05$8.21▼$11.98$445.78M0.36379,154 shs46,996 shsTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%+2.15%EPZMEpizyme0.00%0.00%0.00%0.00%0.00%INSMInsmed+4.81%-3.37%-4.39%-7.77%+33.63%TBPHTheravance Biopharma-2.54%-4.85%+3.36%-6.01%-18.12%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AINSMInsmed4.0307 of 5 stars4.51.00.04.52.50.00.6TBPHTheravance Biopharma2.0881 of 5 stars3.52.00.00.01.92.50.6TPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS HealthN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AINSMInsmed3.00Buy$44.9274.16% UpsideTBPHTheravance Biopharma3.00Buy$20.50123.31% UpsideTPTXTurning Point TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest TBPH, BLUSF, INSM, EPZM, and TPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$48.004/12/2024TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/11/2024INSMInsmedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.004/1/2024INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.002/27/2024INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.002/27/2024INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$46.002/15/2024INSMInsmedWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00EPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72INSMInsmed$305.21M12.55N/AN/A($2.32) per share-11.12TBPHTheravance Biopharma$57.42M7.76N/AN/A$4.28 per share2.14TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/AEPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AINSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)TBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)TPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest TBPH, BLUSF, INSM, EPZM, and TPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 million2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87EPZMEpizymeN/A5.355.19INSMInsmedN/A4.123.75TBPHTheravance BiopharmaN/A5.395.39TPTXTurning Point TherapeuticsN/A16.8316.83OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/AEPZMEpizyme76.45%INSMInsmedN/ATBPHTheravance Biopharma99.10%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%EPZMEpizyme23.40%INSMInsmed4.60%TBPHTheravance Biopharma6.90%TPTXTurning Point Therapeutics8.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableEPZMEpizyme250168.33 million128.97 millionOptionableINSMInsmed373148.55 million141.72 millionOptionableTBPHTheravance Biopharma35948.56 million45.21 millionOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableTBPH, BLUSF, INSM, EPZM, and TPTX HeadlinesSourceHeadlineGlass System in Turning Point Residencearchdaily.com - April 2 at 10:51 AMBid to remove prosecutors sets up turning point in Trump’s Georgia casepolitico.com - February 19 at 11:51 PMTurning Point Brands Inc.wsj.com - February 17 at 11:42 PMAlzheimer’s: A Turning Point?bbc.co.uk - February 12 at 4:29 PMTurning Point Brands Inc (TPB)investing.com - February 10 at 7:36 PMCormorant Asset Management, LP's Net Worthbenzinga.com - February 10 at 7:36 PMSolving quadratic equations - Edexcelbbc.co.uk - January 15 at 9:15 AMCOP15: A Turning Point for Investor Approaches to Biodiversitymorningstar.com - December 19 at 12:52 PMTurning Point USA: Are conservatives fighting back on campus?bbc.com - December 16 at 3:14 PMBMS bet looking good as Augtyro approved in ROS1-positive NSCLCthepharmaletter.com - November 16 at 12:30 PMPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodulster.ac.uk - October 29 at 7:58 PMA Turning Point for Japan-US Climate Cooperation?thediplomat.com - October 28 at 1:00 PMWhat to know about the Turning Point USA incident on Arizona State University's campusazcentral.com - October 28 at 1:00 PMRight-wingers start to turn on this pro-Trump propaganda groupmsnbc.com - October 28 at 1:00 PMUAW, Detroit Three careen toward another Friday turning pointautoblog.com - October 16 at 6:04 PMTrump's youth whisperers living large as MAGA candidates failmsnbc.com - October 14 at 1:16 PMSong Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...Song Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...koimoi.com - October 5 at 8:10 AMThe revised economic figures are a huge lucky break for Sunak – and could be a turning pointindependent.co.uk - September 17 at 4:14 PMDespite previous campus firestorm, Turning Point USA to welcome conservative speakers at ASUazcentral.com - September 15 at 12:34 AMThis law may be the turning point in America’s fight to save the planetmsnbc.com - August 21 at 7:44 AMTattoos have reached a turning point at workft.com - July 29 at 11:36 PMTurning Point’s #ACTCON was a pro-Trump lovefest designed to intimidatemsnbc.com - July 25 at 10:25 AM‘Turning point’ in the fight against Alzheimer’s as drug found to slow diseaseindependent.co.uk - July 23 at 3:37 PMMargaret Thatcher, a turning point in British politicsen.mercopress.com - July 19 at 12:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.EpizymeNASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Turning Point TherapeuticsNASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.